Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3044% below fair value
$3.03−0.02 (-0.66%)
Close on Nov 16, 2026Market cap $244.13MP/E 13.2Yield –
Protalix BioTherapeutics cash
Cash and short-term investments held at the end of each period.
Protalix BioTherapeutics's cash was $27.42M at Jun 30, 2026. For fiscal 2025 it was $14.68M, down 25.7% from the year before. Over ten years it grew -15.2% a year on average. The highest annual figure on record is $86.40M in fiscal 2013.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.68M | -25.7% |
| FY2024 | Dec 31, 2024 | $19.76M | -16.4% |
| FY2023 | Dec 31, 2023 | $23.63M | +38.1% |
| FY2022 | Dec 31, 2022 | $17.11M | -56.1% |
| FY2021 | Dec 31, 2021 | $38.99M | +113.4% |
| FY2020 | Dec 31, 2020 | $18.27M | +2.7% |
| FY2019 | Dec 31, 2019 | $17.79M | -52.9% |
| FY2018 | Dec 31, 2018 | $37.81M | -26.1% |
| FY2017 | Dec 31, 2017 | $51.16M | -19.1% |
| FY2016 | Dec 31, 2016 | $63.28M | -17.1% |
| FY2015 | Dec 31, 2015 | $76.37M | +39.5% |
| FY2014 | Dec 31, 2014 | $54.77M | -36.6% |
| FY2013 | Dec 31, 2013 | $86.40M | +66.0% |
| FY2012 | Dec 31, 2012 | $52.04M | +92.7% |
| FY2011 | Dec 31, 2011 | $27.00M | -24.8% |
| FY2010 | Dec 31, 2010 | $35.90M | -55.8% |
| FY2009 | Dec 31, 2009 | $81.27M | +90.8% |
| FY2008 | Dec 31, 2008 | $42.60M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $27.42M | +53.2% |
| Q1 FY2026 | Mar 31, 2026 | $41.00M | +110.7% |
| Q4 FY2025 | Dec 31, 2025 | $14.68M | -25.7% |
| Q3 FY2025 | Sep 30, 2025 | $13.65M | -50.2% |
| Q2 FY2025 | Jun 30, 2025 | $17.90M | -23.5% |
| Q1 FY2025 | Mar 31, 2025 | $19.46M | -28.5% |
| Q4 FY2024 | Dec 31, 2024 | $19.76M | -16.4% |
| Q3 FY2024 | Sep 30, 2024 | $27.41M | +34.3% |
| Q2 FY2024 | Jun 30, 2024 | $23.40M | -51.4% |
| Q1 FY2024 | Mar 31, 2024 | $27.21M | -17.6% |
| Q4 FY2023 | Dec 31, 2023 | $23.63M | +38.1% |
| Q3 FY2023 | Sep 30, 2023 | $20.41M | +90.4% |
| Q2 FY2023 | Jun 30, 2023 | $48.18M | +285.7% |
| Q1 FY2023 | Mar 31, 2023 | $33.04M | +95.6% |
| Q4 FY2022 | Dec 31, 2022 | $17.11M | -56.1% |
| Q3 FY2022 | Sep 30, 2022 | $10.72M | +0.7% |
| Q2 FY2022 | Jun 30, 2022 | $12.49M | -63.1% |
| Q1 FY2022 | Mar 31, 2022 | $16.89M | -14.8% |
| Q4 FY2021 | Dec 31, 2021 | $38.99M | +113.4% |
| Q3 FY2021 | Sep 30, 2021 | $10.64M | -21.4% |
| Q2 FY2021 | Jun 30, 2021 | $33.88M | +139.2% |
| Q1 FY2021 | Mar 31, 2021 | $19.83M | +11.5% |
| Q4 FY2020 | Dec 31, 2020 | $18.27M | -14.8% |
| Q3 FY2020 | Sep 30, 2020 | $13.53M | -46.1% |
| Q1 FY2020 | Mar 31, 2020 | $14.17M | -53.3% |
| Q4 FY2019 | Dec 31, 2019 | $17.79M | -52.9% |
| Q3 FY2019 | Sep 30, 2019 | $21.44M | -48.8% |
| Q2 FY2019 | Jun 30, 2019 | $25.10M | -11.4% |
| Q1 FY2019 | Mar 31, 2019 | $30.36M | -26.5% |
| Q4 FY2018 | Dec 31, 2018 | $37.81M | -26.1% |
| Q3 FY2018 | Sep 30, 2018 | $41.87M | +25.0% |
| Q2 FY2018 | Jun 30, 2018 | $28.33M | -18.0% |
| Q1 FY2018 | Mar 31, 2018 | $41.32M | -13.9% |
| Q4 FY2017 | Dec 31, 2017 | $51.16M | -19.1% |
| Q3 FY2017 | Sep 30, 2017 | $33.48M | -34.8% |
| Q2 FY2017 | Jun 30, 2017 | $34.53M | -36.8% |
| Q1 FY2017 | Mar 31, 2017 | $48.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $63.28M | – |
| Q3 FY2016 | Sep 30, 2016 | $51.32M | – |
| Q2 FY2016 | Jun 30, 2016 | $54.63M | – |
See a number that looks wrong?